- Home
- SFL vs IMCR Comparison
SFL vs IMCR Comparison
Compare SFL & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SFL | IMCR |
|---|---|---|
| Founded | 2003 | 2008 |
| Country | Bermuda | United Kingdom |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2004 | 2016 |
Fundamental Metrics
Financial Performance| Metric | SFL | IMCR |
|---|---|---|
| Price | $10.90 | $29.34 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 10 |
| Target Price | $12.00 | ★ $66.33 |
| AVG Volume (30 Days) | ★ 1.1M | 426.1K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | ★ 7.39% | N/A |
| EPS Growth | N/A | ★ 30.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $249,428,000.00 |
| Revenue This Year | N/A | $14.57 |
| Revenue Next Year | $13.07 | $8.21 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 43.05 |
| 52 Week Low | $6.73 | $27.47 |
| 52 Week High | $11.28 | $40.71 |
Technical Indicators
Market Signals| Indicator | SFL | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 54.99 | 36.11 |
| Support Level | $9.83 | $28.90 |
| Resistance Level | $11.15 | $33.48 |
| Average True Range (ATR) | 0.26 | 1.12 |
| MACD | -0.03 | -0.20 |
| Stochastic Oscillator | 51.97 | 16.86 |
Price Performance
Historical ComparisonAbout SFL SFL Corporation Ltd
SFL Corp Ltd is an international ship-owning and chartering company. The company is engaged in transporting crude oil and oil products, dry bulk and containerized cargoes, freight of rolling cargo, and offshore drilling and related activities. The company operates as a single reportable segment, generating revenue from long-term, fixed-rate charters. Its Additional revenue sources include sales-type lease interest income, voyage charter and pool revenues, and drilling contract revenues.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.